Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Oh hey there…another Top 5 topics you need to know from outside Europe this week.

Hope you enjoy and if you have time, give us some feedback!

 FOUNDER OF THERANOS: MODERN DIAGNOSIS OF DISEASE IS TOO LATE

CC Alden Chadwick

CC Alden Chadwick

ADVERTISEMENT

“If you look up the word ‘diagnose’ in the dictionary, it’ll say ‘to determine the presence of disease from its signs and symptoms'” says Elizabeth Holmes, billionaire founder of Theranos. She goes on to explain that by this point, “no matter what therapy you put [someone] on, you’re going to lose them.”

READ MORE ON TECH INSIDER…

SHORT SELLERS MAKING MOST OF DEVALUED BIOTECH COMPANIES

CC Stéfan

CC Stéfan

According to a report by the Financial Times, short sellers have taken a distinct interest in newly public, life science companies. The findings of this report show ‘shorts’ are betting the industry’s recent surge of biotech IPOs will decrease and their stock will devalue, which was seen last month.

READ MORE ON FIERCEBIOTECH… 

BIOPHARMA INVESTMENT HAS INCREASED SINCE 2011

lab_one.jpg

Investments in biopharma have surpassed that of IT/software according to a study published on Life Sci VC. Results obtained showed the venture capital returns for biopharma were at a staggering 69.9% compared with that of IT/software, at 45.0% between 2011-2015.

READ MORE ON LIFE SCI VC…

GOOGLE INCREASES PRESENCE IN BIOTECH WITH ACQUISITION OF LIFT LABS

Google alphabet biotech

On Wednesday Google announced its acquisition of Lift Labs, a small company that manufactures a high-tech spoon that stabilizes food, targeted for those whom have Parkinson’s disease or tremors. The price of the acquisition was undisclosed.

READ MORE ON FORBES…

BIOGENS $544 MILLION DEAL FOR PHASE II AUTOIMMUNE DRUG

Histopathological image of the active stage of ulcerative colitis. Endoscopic biopsy. Hematoxylin & eosin stain. CC KGH

Histopathological image of the active stage of ulcerative colitis. Endoscopic biopsy. Hematoxylin & eosin stain. CC KGH

Biogen has made a deal worth $544 million with Mitsubishi Tanabe for MT-1303, an oral receptor drug for multiple sclerosis which has potential for treating Irritable bowel disease (IBD). This deal may put them head-to-head with other pharma companies, such as Celgene and Arena Pharmaceuticals which also have IBD treatments in the pipeline.

READ MORE ON FIERCEBIOTECH…

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.